Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Reyoungel Medical Technology is a China-based aesthetic medical products company focused on injectable cross-linked hyaluronic acid dermal fillers and related beauty-medical consumables. The company markets the Reyoungel brand and presents itself as part of or closely associated with Bioha Laboratories, an organization established in 2003 with experience in medical sodium hyaluronate gel manufacturing. Its commercial portfolio includes multiple HA filler formulations, PDO thread lift products, cannulas, mesotherapy needles, and topical/post-care products for aesthetic procedures. Reyoungel appears to operate primarily as a manufacturer and exporter rather than a drug developer, with products distributed internationally across more than 30 countries. The company emphasizes ISO 13485 certification, CE-marked Class III devices, and GMP-oriented manufacturing on its marketing materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Reyoungel Medical Technology.